Where I see patients (3)
Selected research
-
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.
Haematologica
-
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Cell reports. Medicine
-
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
American journal of hematology
Contact me
Translation, please